OREVGLO Trademark

Trademark Overview

On Tuesday, January 30, 2024, a trademark application was filed for OREVGLO with the United States Patent and Trademark Office. The USPTO has given the OREVGLO trademark a serial number of 98382882. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, November 5, 2024. This trademark is owned by Pfizer Inc.. The OREVGLO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; Pharmaceutical preparations for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of hypoxic and hypoxemic conditions
orevglo

General Information

Serial Number98382882
Word MarkOREVGLO
Filing DateTuesday, January 30, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 10, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use; Pharmaceutical preparations for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of hypoxic and hypoxemic conditions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 30, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192

Trademark Events

Event DateEvent Description
Tuesday, January 30, 2024NEW APPLICATION ENTERED
Thursday, May 30, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 7, 2024ASSIGNED TO EXAMINER
Thursday, August 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 21, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 10, 2024PUBLISHED FOR OPPOSITION
Tuesday, September 10, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 5, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Related Keywords

orevglo preparations pharmaceutical disorders treatment obesity diabetes namely stroke anti pain